Oportuzumab monatox

Oportuzumab monatox (proposed INN, trade name Vicineum) is an antineoplastic. Chemically, oportuzumab is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A (which is reflected by the monatox in the drug's name).[1]

Oportuzumab monatox
Monoclonal antibody
TypeSingle-chain variable fragment
SourceHumanized
TargetEpCAM
Clinical data
Trade namesVicineum
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC3072H4723N877O952S12
Molar mass69558.48 g·mol−1
 NY (what is this?)  (verify)

The drug was originally developed by Canadian-based Viventia Bio Inc. The company was acquired by Cambridge(MA)-based Eleven Biotherapeutics in 2016 which then changed its name to Sesen Bio.[2] In 2019 Sesen Bio reported updated, preliminary primary and secondary endpoint data from the company's Phase 3 VISTA trial further supporting the strong benefit-risk profile of Vicineum for the potential treatment of patients with high-risk, bacillus Calmette-Guérin(BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).[3] The Company applied for approval of Vicineum by the United States Food and Drug Administration und the European Medicines Agency.

References
  1. International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
  2. Alex Keown: Eleven Biotherapeutics Changes Name to Sesen Bio to Reflect Commitment to Oncology Therapies. Biospace.com, May 16, 2018.
  3. Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer. Businesswire.com, August 08, 2019

Vol 24, No 18S (June 20 Supplement), 2006: 4580


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.